Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Nov 3;304(17):1903-11.
doi: 10.1001/jama.2010.1510.
Rema Raman, Ronald G Thomas, Karin Yurko-Mauro, Edward B Nelson, Christopher Van Dyck, James E Galvin, Jennifer Emond, Clifford R Jack Jr, Michael Weiner, Lynne Shinto, Paul S Aisen
Affiliations
- PMID: 21045096
- PMCID: PMC3259852
- DOI: 10.1001/jama.2010.1510
Randomized Controlled Trial
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Joseph F Quinn et al. JAMA. 2010.
Abstract
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.
Objective: To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease.
Design, setting, and patients: A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14-26) was conducted between November 2007 and May 2009 at 51 US clinical research sites of the Alzheimer's Disease Cooperative Study.
Intervention: Participants were randomly assigned to algal DHA at a dose of 2 g/d or to identical placebo (60% were assigned to DHA and 40% were assigned to placebo). Duration of treatment was 18 months.
Main outcome measures: Change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) sum of boxes. Rate of brain atrophy was also determined by volumetric magnetic resonance imaging in a subsample of participants (n = 102).
Results: A total of 402 individuals were randomized and a total of 295 participants completed the trial while taking study medication (DHA: 171; placebo: 124). Supplementation with DHA had no beneficial effect on rate of change on ADAS-cog score, which increased by a mean of 7.98 points (95% confidence interval [CI], 6.51-9.45 points) for the DHA group during 18 months vs 8.27 points (95% CI, 6.72-9.82 points) for the placebo group (linear mixed-effects model: P = .41). The CDR sum of boxes score increased by 2.87 points (95% CI, 2.44-3.30 points) for the DHA group during 18 months compared with 2.93 points (95% CI, 2.44-3.42 points) for the placebo group (linear mixed-effects model: P = .68). In the subpopulation of participants (DHA: 53; placebo: 49), the rate of brain atrophy was not affected by treatment with DHA. Individuals in the DHA group had a mean decline in total brain volume of 24.7 cm(3) (95% CI, 21.4-28.0 cm(3)) during 18 months and a 1.32% (95% CI, 1.14%-1.50%) volume decline per year compared with 24.0 cm(3) (95% CI, 20-28 cm(3)) for the placebo group during 18 months and a 1.29% (95% CI, 1.07%-1.51%) volume decline per year (P = .79).
Conclusion: Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease.
Trial registration: clinicaltrials.gov Identifier: NCT00440050.
Figures
Figure 1
Flow of Patients in the Alzheimer’s Disease Cooperative Study (ADCS) Docosahexaenoic Acid Supplementation Trial Study partner issue is included as a reason for discontinuation because of the requirement for a study partner to participate in several of the key outcome measures in this trial (eg, Clinical Dementia Rating sum of boxes, ADCS activities of daily living, and Neuropsychiatric Inventory). There were no significant differences in incidence of dropout, adverse events, or serious adverse events (Table 2). aThere could be more than 1 reason for exclusion or study discontinuation.
Figure 2
Change in Primary and Secondary Outcome Measures in the Alzheimer’s Disease Cooperative Study (ADCS) Docosahexaenoic Acid (DHA) Supplementation Trial All randomized participants were included in these intention-to-treat analyses. Error bars indicate 95% confidence intervals. There was no effect of DHA on rate of cognitive change on the Alzheimer’s Disease Assessment Scale (ADAS; linear mixed-effects model: P = .41), Clinical Dementia Rating (CDR) sum of boxes (linear mixed-effects model: P = .68), ADCS activities of daily living scale (linear mixed-effects model: P = .38), or Neuropsychiatric Inventory (NPI; linear mixed-effects model: P = .11). Scores for the ADAS-cog and CDR sum of boxes were the prespecified primary outcome measures; others were secondary outcomes.
Figure 3
Rate of Cognitive Change on Alzheimer’s Disease Assessment Scale (ADAS) Divided by Apolipoprotein E (APOE) Genotype Error bars indicate 95% confidence intervals. The linear mixed-effects analysis finds no effect of docosahexaenoic acid (DHA) on the rate of ADAS-cog change in APOE ε4–positive participants but when the analysis is confined to APOE ε4-negative participants, the rate of change in ADAS-cog is slower in participants treated with DHA than in participants treated with placebo (linear mixed-effects model: P = .03). There was no evidence of a DHA effect on Clinical Dementia Rating sum of boxes, Alzheimer’s Disease Cooperative Study activities of daily living, or Neuropsychiatric Inventory on rates of brain atrophy (see “Results” section).
Comment in
- Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results.
Yaffe K. Yaffe K. JAMA. 2010 Nov 3;304(17):1952-3. doi: 10.1001/jama.2010.1625. JAMA. 2010. PMID: 21045105 No abstract available. - Docosahexaenoic acid supplementation and Alzheimer disease.
Umhau JC. Umhau JC. JAMA. 2011 Feb 16;305(7):672; author reply 673. doi: 10.1001/jama.2011.140. JAMA. 2011. PMID: 21325181 No abstract available.
Similar articles
- High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study. Aisen PS, et al. JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774. JAMA. 2008. PMID: 18854539 Free PMC article. Clinical Trial. - Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Freund-Levi Y, et al. Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402. Arch Neurol. 2006. PMID: 17030655 Clinical Trial. - Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators. Wilcock GK, et al. Lancet Neurol. 2008 Jun;7(6):483-93. doi: 10.1016/S1474-4422(08)70090-5. Epub 2008 Apr 29. Lancet Neurol. 2008. PMID: 18450517 Clinical Trial. - Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M, Grimley EJ, Areosa SA. Malouf M, et al. Cochrane Database Syst Rev. 2003;(4):CD004514. doi: 10.1002/14651858.CD004514. Cochrane Database Syst Rev. 2003. PMID: 14584018 Updated. Review. - Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline.
Yurko-Mauro K. Yurko-Mauro K. Curr Alzheimer Res. 2010 May;7(3):190-6. doi: 10.2174/156720510791050911. Curr Alzheimer Res. 2010. PMID: 20088810 Review.
Cited by
- ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial.
Shinto LH, Murchison CF, Silbert LC, Dodge HH, Lahna D, Rooney W, Kaye J, Quinn JF, Bowman GL. Shinto LH, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2426872. doi: 10.1001/jamanetworkopen.2024.26872. JAMA Netw Open. 2024. PMID: 39088212 Free PMC article. Clinical Trial. - Potential role and therapeutic implications of glutathione peroxidase 4 in the treatment of Alzheimer's disease.
Shen Y, Zhang G, Wei C, Zhao P, Wang Y, Li M, Sun L. Shen Y, et al. Neural Regen Res. 2025 Mar 1;20(3):613-631. doi: 10.4103/NRR.NRR-D-23-01343. Epub 2024 Mar 1. Neural Regen Res. 2025. PMID: 38886929 Free PMC article. - Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems.
Loeffler DA. Loeffler DA. J Alzheimers Dis. 2024;100(2):379-411. doi: 10.3233/JAD-240212. J Alzheimers Dis. 2024. PMID: 38875041 Free PMC article. Review. - The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease.
Dakterzada F, Jové M, Cantero JL, Mota-Martorell N, Pamplona R, Piñoll-Ripoll G. Dakterzada F, et al. Alzheimers Dement. 2024 May;20(5):3322-3333. doi: 10.1002/alz.13792. Epub 2024 Mar 27. Alzheimers Dement. 2024. PMID: 38534027 Free PMC article. - Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials.
Lu TV, Grill JD, Gillen DL; Alzheimer’s Disease Cooperative Study. Lu TV, et al. J Alzheimers Dis. 2024;98(2):729-738. doi: 10.3233/JAD-231283. J Alzheimers Dis. 2024. PMID: 38427487 Free PMC article.
References
- Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol. 1997;145(1):33–41. - PubMed
- Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol. 1997;42(5):776–782. - PubMed
- Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60(7):940–946. - PubMed
- Lim WS, Gammack JK, Van Niekerk J, Dangour AD. Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev. 2006;(1):CD005379. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01-AG10483/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- U01 AG010483/AG/NIA NIH HHS/United States
- U01 AG010483-17/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical